Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (21-30 of 442) with videos related to

Pageof 45
Sort By:
Journal for Immunotherapy of Cancer|July 11, 2024
A crisis in clinical researchDavid S Hong, Patricia LoRusso, Mario Sznol
Frontiers in Oncology|May 17, 2024
KRAS G12C inhibitor combination therapies: current evidence and challengeHirotaka Miyashita, Shumei Kato, David S Hong
Clinical Advances in Hematology & Oncology : H&O|July 2, 2024
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancersDavid S Hong, Alexander Drilon, Lori J Wirth
Journal of Developmental and Behavioral Pediatrics : JDBP|July 12, 2011
Psychosocial functioning and social cognitive processing in girls with Turner syndromeDavid S Hong, Bria Dunkin, Allan L Reiss
Translation (Austin, Tex.)|January 19, 2016
Targeting translation initiation in breast cancerArgun Akcakanat, David S Hong, Funda Meric-Bernstam
Clinical Advances in Hematology & Oncology : H&O|July 2, 2024
Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancerDavid S Hong, Alexander Drilon, Lori J Wirth
Cancer Treatment Reviews|September 10, 2016
RNA-targeted therapeutics in cancer clinical trials: Current status and future directionsPedro Barata, Anil K Sood, David S Hong
Cancer|September 13, 2007
Interleukin-6 and its receptor in cancer: implications for translational therapeuticsDavid S Hong, Laura S Angelo, Razelle Kurzrock
Proceedings of the National Academy of Sciences of the United States of America|February 27, 2016
Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside reportVivek Subbiah, David S Hong, Funda Meric-Bernstam
JCO Precision Oncology|September 28, 2023
Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase InhibitorsMarcia S Brose, David S Hong, Alexander Drilon
Pageof 45

Showing results (21-30 of 442) with videos related to

Sort By:
Pageof 45
Journal for Immunotherapy of Cancer|July 11, 2024
A crisis in clinical researchDavid S Hong, Patricia LoRusso, Mario Sznol
Frontiers in Oncology|May 17, 2024
KRAS G12C inhibitor combination therapies: current evidence and challengeHirotaka Miyashita, Shumei Kato, David S Hong
Clinical Advances in Hematology & Oncology : H&O|July 2, 2024
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancersDavid S Hong, Alexander Drilon, Lori J Wirth
Journal of Developmental and Behavioral Pediatrics : JDBP|July 12, 2011
Psychosocial functioning and social cognitive processing in girls with Turner syndromeDavid S Hong, Bria Dunkin, Allan L Reiss
Translation (Austin, Tex.)|January 19, 2016
Targeting translation initiation in breast cancerArgun Akcakanat, David S Hong, Funda Meric-Bernstam
Clinical Advances in Hematology & Oncology : H&O|July 2, 2024
Q&A: Barriers to testing for NTRK fusions in metastatic lung and thyroid cancerDavid S Hong, Alexander Drilon, Lori J Wirth
Cancer Treatment Reviews|September 10, 2016
RNA-targeted therapeutics in cancer clinical trials: Current status and future directionsPedro Barata, Anil K Sood, David S Hong
Cancer|September 13, 2007
Interleukin-6 and its receptor in cancer: implications for translational therapeuticsDavid S Hong, Laura S Angelo, Razelle Kurzrock
Proceedings of the National Academy of Sciences of the United States of America|February 27, 2016
Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside reportVivek Subbiah, David S Hong, Funda Meric-Bernstam
JCO Precision Oncology|September 28, 2023
Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase InhibitorsMarcia S Brose, David S Hong, Alexander Drilon
Pageof 45